Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.
This article describes the development of the protocol for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Alzheimer's disease trial, which was developed in collaboration with the National Institute of Mental Health to assess the effectiveness of atypical antipsychotics for psychosis and/or agitation occurring in outpatients with Alzheimer's disease. The article provides a detailed description of the methodology used in the trial as well as the clinical outcomes and effectiveness measures incorporated into it, discussing the most salient issues encountered in developing the design of the trial, as well as the unique features of the trial.
Schneider
Lon S
LS
Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine, University of Southern California, Los Angeles 90033, USA. lschneid@usc.edu
Ismail
M Saleem
MS
Dagerman
Karen
K
Davis
Sonia
S
Olin
Jason
J
McManus
Dennis
D
Pfeiffer
Eric
E
Ryan
J Michael
JM
Sultzer
David L
DL
Tariot
Pierre N
PN
D000368:Aged; D000465:Algorithms; D000544:Alzheimer Disease / Q000175:diagnosis / Q000523:psychology*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D004311:Double-Blind Method; D006801:Humans; D010043:Outcome and Process Assessment, Health Care; D011595:Psychomotor Agitation / Q000188:drug therapy* / Q000209:etiology*; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000209:etiology*; D016032:Randomized Controlled Trials as Topic / Q000592:standards*
D014150:Antipsychotic Agents